Atria Investments Inc Acquires Shares of 3,587 Exact Sciences Co. (NASDAQ:EXAS)

Atria Investments Inc bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,587 shares of the medical research company’s stock, valued at approximately $244,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Itau Unibanco Holding S.A. acquired a new stake in Exact Sciences during the second quarter worth approximately $29,000. Capital Performance Advisors LLP bought a new position in shares of Exact Sciences in the third quarter worth $35,000. Vestor Capital LLC acquired a new position in Exact Sciences in the third quarter valued at about $46,000. V Square Quantitative Management LLC bought a new stake in Exact Sciences during the third quarter worth about $47,000. Finally, EverSource Wealth Advisors LLC lifted its position in Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after purchasing an additional 340 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on EXAS shares. Piper Sandler dropped their target price on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday. The Goldman Sachs Group reduced their target price on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upped their price objective on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $74.47.

Insider Activity

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the sale, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at $893,060. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.36% of the company’s stock.

Exact Sciences Stock Down 0.3 %

Shares of EXAS opened at $52.91 on Friday. The stock’s 50-day moving average price is $64.79 and its two-hundred day moving average price is $55.87. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a market capitalization of $9.79 billion, a PE ratio of -45.22 and a beta of 1.27. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. On average, analysts anticipate that Exact Sciences Co. will post -1.08 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.